Eli Lilly (LLY) Perpetuals on Hyperliquid

Eli Lilly is a pharmaceutical giant behind blockbuster weight-loss drugs Mounjaro and Zepbound. Trade LLY perpetual futures 24/7 on Hyperliquid via trade.xyz.

LLY is a cash-settled perpetual futures contract on Hyperliquid, deployed via trade.xyz as a HIP-3 builder market. Unlike traditional futures, there is no expiry date and no physical delivery — positions roll continuously with funding rates settling every hour. All margin is denominated in USDC, and you can trade with up to 10x leverage.

HIP-3 markets extend Hyperliquid beyond crypto, bringing equities, commodities, and indices on-chain with 24/7 trading, no KYC, and the same on-chain order book infrastructure that powers Hyperliquid's native perpetuals.

Hyperliquid offers distinct advantages for equity traders: gasless execution means zero transaction costs beyond the maker/taker spread, no KYC or identity verification is required to open an account, and trading is available 24/7 including weekends and holidays when traditional equity markets are closed. Self-custody ensures you retain full control of your funds at all times.

LLY-PERP tracks the spot Eli Lilly share price via the trade.xyz oracle with hourly funding. Lilly is a mega-cap pharma whose valuation has been rebuilt around the GLP-1 franchise — tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity — so the trade is really a bet on the incretin/obesity-drug story more than on the broader drug pipeline. The distinctive catalysts here have no overlap with anything else on this venue. I watch prescription and script-trend data for Zepbound and Mounjaro, manufacturing-capacity expansions (supply has been the binding constraint on this category), payer and insurance-coverage decisions, and above all clinical and regulatory readouts: trial results, FDA decisions, and label expansions into adjacent indications like sleep apnea and cardiovascular outcomes. The oral GLP-1 program (orforglipron) is a particularly binary catalyst — a strong or weak readout can reprice the stock sharply. Competitive dynamics with Novo Nordisk are the other constant input; share-of-market and head-to-head trial data move both names together. Earnings are quarterly, but the trial and FDA calendar often matters more. Realized vol spikes around data readouts that can land any time, which is where round-the-clock USDC settlement helps — I can react the moment a readout or FDA headline prints. Up to the leverage cap on this page, no KYC.